SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE is trending as the community rallies around the OG meme coin, emphasizing its staying power compared to other crypto projects. With a strong focus on community-driven initiatives and meme creation, supporters are actively pushing for increased visibility and a "moonshot" listing. The overall sentiment is bullish, with community members encouraging others to "RAGE HARDER" and dismissing bearish market conditions.

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company was founded in 1989 and is headquartered in Los Angeles, CA.

Armata Pharmaceuticals Inc

Armata Pharmaceuticals is trending due to positive Phase 2a clinical trial results for its AP-SA02 drug targeting Staphylococcus aureus bacteremia, with potential as a new standard of care; the study showed high responder rates and zero relapse in MRSA cases. The community is discussing the potential for a Phase 3 study and commercialization, but also noting the company's cash position and potential for future offerings, as well as potential government stake.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is trending despite a significant intraday drop following news of a $5 billion AI infrastructure lease, with community members pointing to potential short-selling tactics or market manipulation. The community is actively discussing the long-term implications of the deal, speculating on the identity of the hyperscaler involved (potential partnership with Oracle). Many express bullish sentiment based on the company's fundamentals and the potential for long-term growth in the AI sector, viewing the current price action as a buying opportunity.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is facing a downturn, with community members pointing to overall market weakness and sector-specific concerns as potential catalysts. The conversation highlights a mix of frustration and bargain-hunting, as investors debate whether the dip represents a buying opportunity or a sign of deeper issues. Despite the current price action, some bulls remain confident in NBIS's long-term prospects due to its AI infrastructure and key partnerships.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending downwards following its Q3 earnings report, with discussions centering on a missed EPS target attributed to a Brazilian tax dispute. While revenue growth remains solid and ad revenue is expected to double, some investors are concerned about valuation and are debating whether this is a buying opportunity or a sign of deeper issues, while others are mentioning subscriber decline as a worry.

Applied DNA Sciences, Inc. is a biotechnology company, which engages in the development and commercialization of technologies to produce and detect deoxyribonucleic acid and ribonucleic acid. It operates through the following segments: Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment consists of the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and, the development and sale of a proprietary RNAP for use in the production of mRNA therapeutics. The MDx Testing Services segment develops clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment is involved in the detection of DNA for industrial supply chains and security services. The company was founded in 1983 and is headquartered in Stony Brook, NY.

Applied Dna Sciences Inc

Applied DNA Sciences ($BNBX) is trending as the company pivots towards a BNB-focused digital asset treasury strategy, sparking significant discussion within the investment community. Community members are actively debating the potential for a short squeeze, citing the low float and high short interest, while also considering the implications of a recent private placement. Some are optimistic about the company's new direction and potential gains, while others express skepticism.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets and Data Centers. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

GLXY is trending following a significant earnings beat, with the community actively discussing the disconnect between the strong results and the stock's price action; some speculate about market manipulation and short positions. Despite the positive earnings, the stock experiences volatility, as investors assess its position in both the crypto and AI data center sectors. Upgrades from analysts are coming, with price targets being discussed among community members.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

ARCT is trending due to recent data from its ARCT-032 cystic fibrosis trial, sparking mixed reactions in the community; while some are disappointed by the limited lung function improvement, others are optimistic about the observed mucus plug reduction and potential future catalysts like CSL royalties and possible company acquisition. Discussions revolve around the selloff being overdone, the drug's mechanism potentially working, and the potential for steady recovery.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is experiencing volatility as traders react to news of potential export restrictions to China and fluctuating sentiments around tariffs. The market is seeing aggressive swings, with community members debating whether to buy the dip or brace for a larger correction, with some calling the market action a "scam". Discussions also revolve around potential government actions and their impact on market stability.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending downwards, with community members discussing a potential correction due to high valuation and government regulations impacting AI power centers. Some traders believe the stock is being manipulated by market makers, while others remain bullish, citing the company's long-term potential in AI and data centers, viewing the dip as a buying opportunity. Overall sentiment is mixed, with concerns about short-term volatility amidst broader market fears.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul><li>The company said that treatment-related adverse events were observed in the study for the first few doses but ceased with continuous dosing.</li><li>The Data Monitoring Committee found no convincing evidence that the serious adverse event is related to ARCT-032 and approved the study to proceed. &nbsp;</li></ul>Arcturus Therapeutics Holdings (ARCT) on Wednesday announced interim results from a mid-stage trial of its ARCT-032 therapy in people with cystic fibrosis.In a cohort of the study, six patients with cystic fibrosis received inhaled 10 mg doses of ARCT-032 daily over 28 days.<h2 class="st-heading-2">What’s Driving Down The Stock?</h2>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.arcturusrx.com/news-releases/news-release-details/arcturus-therapeutics-provides-interim-phase-2-data-cystic">reported</a> that treatment-related adverse events were observed in the study during the initial doses but ceased with continuous dosing.However, the Data Monitoring Committee found no convincing evidence that the serious adverse event is related to ARCT-032 and approved the study to proceed, the company said. One treatment-related adverse event also occurred in a participant after the end of the dosing period, it said. Furthermore, the treatment was generally safe and well-tolerated, the company added.However, shares of the company fell 58% on Wednesday. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ARCT">ARCT stock</a> rose from ‘bearish’ to ‘extremely bullish’ over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.<h2 class="st-heading-2">What Are The Firm’s Plans Ahead?</h2>Arcturus noted on Wednesday that an expanded third cohort is ongoing. The company aims to enroll up to six subjects in the cohort if there is a dose escalation response at 15 mg and if ARCT-032 continues to be generally safe and well-tolerated.The company also said that it intends to kickstart a 12-week safety and preliminary efficacy study in up to 20 cystic fibrosis participants in the first half of 2026.Cystic fibrosis (CF) is an inherited genetic disorder that causes thick, sticky mucus to build up in the body's organs, primarily affecting the lungs and pancreas. It is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.<blockquote>“We are particularly encouraged by the early signals of mucus plug reduction in Class I CF participants treated with ARCT-032 because Class I CF individuals do not produce CFTR and therefore do not respond to available CFTR modulator therapy.”— Juergen Froehlich, Chief Medical Officer, Arcturus</blockquote>ARCT stock is down 43% this year and 51% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-to-recall-nearly-13000-vehicles-in-us/cLG57HOR3q4">Tesla To Recall Nearly 13,000 Vehicles In US, But Retail Has Its Eyes Set On Q3 Earnings</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Medical syringe is seen with Arcturus Therapeutics company logo displayed on a screen in the background in this illustration photo taken in Poland on June 16, 2020. (Photo Illustration by Jakub Porzycki/NurPhoto via Getty Images)

Arcturus Therapeutics Stock Plunges Over 58% Today: What’s Causing The Sell-Off?

The company said that treatment-related adverse events were observed in the study for the first few doses but ceased with continuous dosing.

Equity

Zacks.com featured highlights include Flux Power, Aura Minerals, Arcturus Therapeutics and Sterling Infrastructure

Flux Power, Aura Minerals, Arcturus Therapeutics, and Sterling Infrastructure show strong price momentum amid market uncertainty.

Arcturus Therapeutics (ARCT) Moves 7.7% Higher: Will This Strength Last?

Arcturus Therapeutics (ARCT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

4 Stocks With Recent Price Strength to Maximize Your Gains

FLUX, AUGO, ARCT and STRL are showing notable price strength amid a volatile market.

Are Medical Stocks Lagging  Aquestive Therapeutics (AQST) This Year?

Here is how Aquestive Therapeutics (AQST) and Arcturus Therapeutics (ARCT) have performed compared to their sector so far this year.

Arcturus Therapeutics (ARCT) is on the Move, Here's Why the Trend Could be Sustainable 

Arcturus Therapeutics (ARCT) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Recursion Pharmaceuticals (RXRX) Surges 8.2%: Is This an Indication of Further Gains?

Recursion Pharmaceuticals (RXRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Arcturus Therapeutics (ARCT) Surges 8.7%: Is This an Indication of Further Gains?

Arcturus Therapeutics (ARCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Should You Buy Arcturus Therapeutics (ARCT) After Golden Cross?

Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?

Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of +69.37% and +20.84%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Current Price	$10.89
Prev Close	$23.16
Open	$9.98
Dividend Yield	0.00%
50-Day Moving Average	$19.14
Beta	1.53
Avg. Volume	654,047.71
PE Ratio	-10.41

52-Week High	$24.17
52-Week Low	$8.04
Market Capitalization	$628.9M
EPS (Annual)	-$3.00
Price to Book	2.72
Revenue Per Employee	$786,301.14
Enterprise Value/EBITDA	N/A

ARCT
Arcturus Therapeutics Holdings Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ARCT News

ARCTArcturus Therapeutics Holdings Inc